C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.

Patil, Namrata S; Zou, Wei; Mocci, Simonetta; Sandler, Alan; Ballinger, Marcus; Flynn, Susan; Kowanetz, Marcin; Hegde, Priti S

Patil, Namrata S; Zou, Wei; Mocci, Simonetta; Sandler, Alan; Ballinger, Marcus; Flynn, Susan; Kowanetz, Marcin; Hegde, Priti S.

Affiliation

Patil NS; Genentech, S. San Francisco, California, United States of America.
Zou W; Genentech, S. San Francisco, California, United States of America.
Mocci S; Genentech, S. San Francisco, California, United States of America.
Sandler A; Genentech, S. San Francisco, California, United States of America.
Ballinger M; Genentech, S. San Francisco, California, United States of America.
Flynn S; Genentech, S. San Francisco, California, United States of America.
Kowanetz M; Genentech, S. San Francisco, California, United States of America.
Hegde PS; Genentech, S. San Francisco, California, United States of America.

PLoS One ; 16(2): e0246486, 2021.

Article in En | MEDLINE | ID: mdl-33534859

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; C-Reactive Protein/metabolism; Carcinoma, Non-Small-Cell Lung/blood; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/blood; Lung Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Platinum/therapeutic use; ROC Curve

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: C-Reactive Protein / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Lung Neoplasms Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google